NeXtGen™ Biologics Secures Favorable Outcome in Inter-Partes Patent Review (BioSpace)
UF Innovate | Accelerate resident client NeXtGen Biologics reported that the U.S. Patent and Trademark Office declined to initiate an inter partes review of its wound care patents, leaving the intellectual property fully enforceable.